阿托伐他汀序贯治疗对老年冠状动脉介入手术对比剂应用后肾功能的影响

目的观察阿托伐他汀序贯治疗对老年患者冠状动脉介入手术对比剂应用后肾功能的影响。方法 80例冠状动脉介入手术老年患者随机分为阿托伐他汀组和对照组,各40例,阿托伐他汀组于冠状动脉介入手术前给予阿托伐他汀序贯治疗(术前12 h阿托伐他汀80 mg,术前2 h阿托伐他汀40 mg,术后40 mg/d),对照组术前及术后均给予其他调脂药常规治疗,观察术前及术后第1天、第2天血肌酐(Scr)、尿素氮(BUN)、内生肌酐清除率(Ccr)、血浆光抑素C(CysC)、肾小球滤过率(GFR)的变化。结果术前两组间Scr、BUN、Ccr、CysC、GFR均无显著变化(P>0.05),阿托伐他汀组术前术后CysC、GFR均无显著变化(P>0.05);术后第1天及第2天两组间CysC、GFR比较,阿托伐他汀组GFR显著高于对照组(P<0.05),CysC显著低于对照组(P<0.05)。结论阿托伐他汀序贯治疗能够预防老年患者冠状动脉介入手术对比剂应用后肾功能恶化。     

强化阿托伐他汀治疗在老年肾功能不全患者PCI术后对比剂肾病预防中的作用

目的探讨经皮冠状动脉介入治疗(PCI)术前强化阿托伐他汀治疗对老年冠心病合并肾功能不全的患者行PCI术后对比剂肾病(CIN)的预防作用及安全性问题。方法择期行PCI术的老年冠心病合并肾功能不全患者250例,随机分成强化阿托伐他汀组(强化组)和常规阿托伐他汀组(常规组)各125例。两组患者在水化的基础上在PCI术前3 d,分别给予阿托伐他汀40 mg/d和10 mg/d口服治疗。观察两组PCI术前及术后72 h血清尿素氮(BUN)、血清肌酐(Scr)、肌酐清除率(Ccr)、肾小球滤过率(eGFR)、β2微球蛋白(β2-MG)、超敏C-反应蛋白hs-(CRP)、白细胞介素(IL)-6、肿瘤坏死因子(TNF)-α、丙氨酸氨基转移酶(ALT)的变化,记录两组CIN的发病率、住院中阿托伐他汀的不良反应。结果 (1)强化组125例患者,发生CIN3例(2.4%);常规组125例患者,发生CIN12例(9.6%),两组CIN发病率差异显著(χ~2=5.75,P<0.05)。多元Logistic回归分析结果亦表明强化阿托伐他汀治疗是CIN的保护因素(OR=0.079,95%CI 0.009~0.725,P=0.025)。(2)强化组与常规组的PCI术前血BUN、Scr、Ccr、eGFR、β2-MG、hs-CRP、IL-6、TNF-α、ALT等差异均无统计学意义(P>0.05)。而PCI术后72 h,两组β2-MG、hs-CRP、IL-6、TNF-α较PCI术前增高;Ccr、eGFR较PCI术前降低(P<0.05)。(3)PCI术后72 h,强化组β2-MG、hs-CRP、IL-6、TNF-α的水平低于常规组;Ccr、eGFR则高于常规组(P<0.05)。(4)两组PCI术后72 h ALT较PCI术前未见明显的升高(P>0.05),两组均未出现阿托伐他汀不良药物反应。结论强化阿托伐他汀治疗对于减少老年冠心病合并肾功能不全患者PCI术后CIN发病率具有一定的益处,具有良好的安全性,其机制可能与他汀抗炎症作用因素有关。     

阿托伐他汀改善冠心病合并肾功能不全患者肾功能

目的探讨阿托伐他汀对冠心病患者肾功能不全的治疗作用。方法回顾性分析2002年1月～2004年1月间我院冠心病合并肾功能不全患者,按是否长期接受阿托伐他汀(lipitor每天40mg),分为阿托伐他汀组46例,男31例,女15例,年龄(52±10)岁,长期接受阿托伐他汀40mg/d治疗;对照组61例,男37例,女24例,年龄(53±11)岁,未曾接受他汀类药物治疗。在2006年3～4月间随访,总随访时间26～50(38±8)个月,观察心血管事件和肾功能。结果阿托伐他汀组血清尿素氮由(11.2±3.0)mmol/L降到(7.6±2.0)mmol/L(P<0.001);血清肌酐由(162±26!mol/L降到121±30!mol/L(P<0.001),54%的患者血清肌酐恢复正常。但对照组并无明显改善(P>0.05)。结论冠心病合并肾功能不全的中国人,长期接受阿托伐他汀40mg/d治疗,能改善肾功能。     

阿托伐他汀对冠脉介入术后肾功能的影响

目的观察不同剂量阿托伐他汀对冠脉造影术或经皮冠状动脉介入术（PCI）术后肾功能的影响,并对其可能机制进行分析。方法纳入我院因急性冠脉综合征（ACS）接受冠脉造影术或PCI术的患者120例,随机分为阿托伐他汀常规剂量治疗组（常规组,20mg/d,n=60）和阿托伐他汀高剂量治疗组（高剂量组,术前40mg/d×3d,术后20mg/d,n=60）。术前、术后24h检测血清不规则趋化因子（FKN）的水平,术前、术后3天和术后7天检测血肌酐（Scr）、评估肾小球滤过率（eGFR）、血胱抑素（Cys）等,同时分析FKN与上述肾功能指标的相关性。结果术后24h高剂量治疗组FKN浓度低于常规剂量治疗组（P〈0.05）;术后3天高剂量组患者Scr、Cys低于常规组,而eGFR则高于常规组,存在统计学差异（P〈0.05）。两组的对比剂肾病（contrast induced nephropathy,CIN）发病率存在统计学差异（6.67%vs.16.67%,P〈0.05）。相关性分析结果显示FKN浓度与患者Scr、Cys水平呈正相关,与eGFR呈负相关（P〈0.05）。结论术前强化阿托伐他汀治疗可预防CIN,其机理可能与FKN有关。     

阿托伐他汀对慢性心力衰竭患者心肾功能的影响

目的探讨阿托伐他汀对慢性心力衰竭(CHF)患者心肾功能的影响。方法将100例慢性心力衰竭患者随机分为常规治疗组(n=50)和阿托伐他汀组(n=50),常规治疗组给予常规抗心力衰竭药物治疗,阿托伐他汀组在常规治疗基础上加用阿托伐他汀20mg,1次/d顿服,观察两组患者治疗3个月前后尿微量清蛋白(MAU)、高敏C反应蛋白(hs-CRP)、左室射血分数(LVEF)、左室舒张末内径(LVEDD)变化。结果 CHF患者治疗3个月后MAU、hs-CRP水平均显著降低(P<0.05),LVEF显著提高(P<0.05),LVEDD显著降低(P<0.05),但阿托伐他汀组与常规治疗组比较,MAU、hs-CRP、LVEDD水平降低更明显(P<0.05),LVEF提高更明显(P<0.05)。结论在常规治疗的基础上加用阿托伐他汀,MAU、LVEF、LVEDD水平改善更明显,提示阿托伐他汀对慢性心力衰竭患者心肾功能有保护作用。     

不同剂量阿托伐他汀对经皮冠状动脉介入术后对比剂急性肾损伤的影响

目的 观察经皮冠状动脉介入术（PCI）前使用不同剂量阿托伐他汀对对比剂诱导的急性肾损伤的影响。方法 入选拟行冠状动脉造影检查及拟行PCI术的患者106例,随机分成2组：20 mg阿托伐他汀组及40 mg阿托伐他汀组;入院24 h内完成常规化验检查、心脏彩色超声检查及肾脏血管超声检查,术后48 h复查肾功能。所有患者手术前当日清晨、术后2 h及术后48 h均留取约5 mL中段尿,用胶乳增强免疫透射比浊法统一测定中性粒细胞明胶酶相关脂质运载蛋白（NGAL）。结果 PCI术后,40 mg阿托伐他汀组与20 mg阿托伐他汀组比较,血清肌酐（77.44±23.14 mmol/L比94.24±36.14 mmol/L,P＝0.014）降低,尿酸（313.05±110.84 μmol/L比354.00±100.66 μmol/L,P＝0.060）降低,肾小球滤过率估计值（92.24±24.74比75.31±31.34,P＝0.009）增高; PCI术后,40 mg阿托伐他汀组与20 mg阿托伐他汀组比较,2 h NGAL（33.13±20.44 μg/L比50.67±46.95 μg/L,P＝0.013）、48 h NGAL（27.56±18.64 μg/L比58.38±56.81 μg/L,P＝0.001）减低;应用对比剂后,20 mg阿托伐他汀组发生对比剂急性肾损伤11例,发生率为20.75%,而40 mg阿托伐他汀组发生对比剂急性肾损伤5例,发生率为9.43%,两组相比差别有统计学意义（P<0.05）。结论 应用对比剂前3天,每天服用40 mg阿托伐他汀较每天服用20 mg阿托伐他汀更能减少对比剂诱导的急性肾损伤的发生。     

阿托伐他汀序贯治疗对老年中、重度慢性肾病患者冠状动脉介入术后对比剂肾病的影响

目的观察阿托伐他汀序贯治疗对老年中、重度慢性肾病(CKD)患者冠状动脉介入(PCI)术后对比剂肾病(CIN)是否具有预防作用。方法入选186例接受PCI治疗的老年中、重度CKD患者,随机分为阿托伐他汀组(96例)和对照组(90例),阿托伐他汀组术前予阿托伐他汀序贯治疗(术前12 h阿托伐他汀80 mg,术前2 h阿托伐他汀40 mg,术后40 mg/d),对照组术前及术后均予其他他汀常规治疗,观察术前、术后第1天、第2天及第3天血肌酐(SCr)、血浆胱抑素C(Cys C)的变化及CIN的发生率。结果 PCI术后对照组中SCr峰值、△SCr、Cys C峰值及△Cys C均显着高于阿托伐他汀组(P0.05)。根据SCr标准的CIN,对照组20例(22.2%),阿托伐他汀组10例(10.4%),CIN的发生率对照组显著高于阿托伐他汀组(P0.05)。根据Cys C标准的CIN,对照组28例(31.1%),阿托伐他汀组14例(14.6%),对照组中CIN的发病率明显高于阿托伐他汀组(P0.01)。结论阿托伐他汀序贯治疗能够预防老年中、重度CKD患者PCI术对比剂应用后肾功能恶化。     

经皮冠状动脉介入术前阿托伐他汀强化治疗对预后的影响

目的评价经皮冠状动脉介入术前患者行阿托伐他汀强化治疗对预后的影响。方法60例入选患者术前被随机分为两组,强化治疗组29例患者,术前12小时内服用阿托伐他汀80mg;对照组31例患者,术前12小时内服用阿托伐他汀20mg,所有患者术后均以阿托伐他汀每日20mg,每日1次长期维持。观察两组患者术前及术后24小时的肌酸激酶同工酶、肌钙蛋白I、C反应蛋白等指标的变化,比较两组在出院3个月时主要不良心血管事件发生率。结果强化治疗组主要不良心血管事件发生率为3．4％,对照组为22．6％（P〈0．05）;与对照组相比,强化治疗组患者术后肌酸激酶同工酶、肌钙蛋白I升高幅度显著减低（P〈0．05）;C反应蛋白升高的幅度低于对照组,但两组比较差异无统计学意义（P〉0．05）。结论PCI术前使用80mg阿托伐他汀同常规使用20mg的剂量相比,强化治疗的患者在短期预后方面获益大。     

不同剂量阿托伐他汀对对比剂致肾功能损伤短期改善的观察

目的观察不同剂量阿托伐他汀(立普妥40 mg和10 mg)对对比剂导致肾功能损伤的短期影响。方法选择80例行冠状动脉造影及诊断治疗的患者,随机分为A组和B组,每组40例。入院后A组予阿托伐他汀40 mg顿服,B组予阿托伐他汀10 mg口服,术前根据患者的一般状况给予充分水化疗法。观察术前、术后血肌酐(Scr)、血β2-微球蛋白(β2-MG)、血清胱抑素C(Cys-c)、高敏C反应蛋白(hs-CRP)及尿α1-微球蛋白(α1-MG)的变化情况。结果术后两组Scr 24 h,72 h较术前升高,但差异无统计学意义。A组术后24 h、72 h血β2-MG明显低于B组[(2.28±0.43)mg/L比(2.66±0.48)mg/L,P<0.01]、[(2.46±0.35)mg/L比(2.71±0.43)mg/L,P<0.01];A组术后24 h、72 h血清Cys-c显著低于B组[(0.90±0.21)mg/L比(1.04±0.32)mg/L,P<0.01]、[(0.84±0.15)mg/L比(0.93±0.20)mg/L,P<0.01]。A组术后24h、72hhs-CRP明显低于B组[(4.33±1.61)mg、L比(6.98±2.55)mg/L,P<0.01]、[(4.27±1.44)mg/L比(5.76±2.02)mg/L,P<0.01];A组术后24h、72h尿α1-MG显著低于B组[(10.60±3.67)mg/L比(9.74±3.04)mg/L,P<0.01]、[(9.74±3.04)mg/L比(12.39±3.96)mg/L,P<0.01]。结论行冠脉造影诊断及治疗患者术前服用40 mg阿托伐他汀较10 mg能减少对比剂对肾功能的损伤。     

阿托伐他汀与瑞舒伐他汀治疗冠心病的临床疗效对比分析

目的观察对比阿托伐他汀与瑞舒伐他汀治疗冠心病的临床疗效。方法选择2011年5月~2012年5月期间我院收治的冠心病患者108例,根据随机性原则将其平均分为研究组与对照组。两组患者均给予基础药物治疗,在此基础上研究组采用瑞舒伐他汀治疗,对照组采用阿托伐他汀治疗。结果治疗1年后,研究组血浆TG、TC、LDL-C指标明显低于对照组(P0.05),HDL-C指标明显高于对照组(P0.05)。结论阿托伐他汀与瑞舒伐他汀治疗冠心病,后者的作用更强、疗效更显著、安全可靠,适于临床广泛应用。     

阿托伐他汀改善对比剂对肾功能的短期影响

目的 观察阿托伐他汀对冠状动脉造影患者肾功能、尿微量蛋白及超敏C反应蛋白(hsCRP)改变的影响.方法 120例单纯冠状动脉造影的患者随机分为他汀组(60例)或对照组(60例),他汀组于冠状动脉造影术前2～3 d始每晚顿服阿托伐他汀20 mg,对照组未服用阿托伐他汀及其他调脂类药.所有患者分别于术前、术后第1天、第2天测定血清肌酐(Scr)及尿素氮(BUN);留尿标本检测尿α1-微球蛋白(α1-MG)、尿转铁蛋白(TRF)和尿微量白蛋白(mALB);测血浆胱抑素C(Cys C)、hsCRP,并根据Cockcrofi-Gauh公式和GFR(ml/min)=74.835/Cys C1.333公式分别计算出肌酐清除率(Ccr)和肾小球滤过率(GFR).结果 (1)对照组:与术前相比,术后第1天α1-MG、TRF、mALB、Cys C及hsCRP均有显著升高(P＜0.01);与术后第1天比较,术后第2天α1-MG、TRF、mALB、Cys C均有显著降低(P＜0.01),但α1-MG、Cys C仍高于术前水平(P＜0.01),而TRF、mALB已恢复到术前水平(P＞0.05);术后第2天hsCRP与术前第l天相比无明显变化(P＞0.05).(2)他汀组:与术前比较,术后第1天及第2天α1-MG、TRF、mALB、Cys C均无明显变化(P＞0.05);术后第1天hsCRP显著升高(P＜0.01);术后第2天hsCRP与术前第1天相比无明显变化(P＞0.05).(3)与他汀组相比较:对照组术后第1天α1-MG、TRF、mALB、Cys C及hsCRP均显著升高(P＜0.01);术后第2天Cys C、α1-MG及hsCRP仍显著升高(P＜0.01),但TRF、mALB均无统计学差异(P＞0.05).两组术前、术后BUN、Scr、Ccr均无明显变化(P＞0.05).结论 对比剂可造成轻微的一过性肾功能损害.阿托伐他汀于冠状动脉造影术前2～3 d给药,可能具有减轻炎症反应、改善患者一过性蛋白尿及GFR降低的作用,提示町能有预防对比剂肾病的作用.     

不同剂量对比剂对冠状动脉造影患者肾功能的影响

目的观察不同剂量造影剂对冠状动脉造影患者肾功能的影响。方法入选2009年12月~2012年7月住院治疗并接受冠脉造影检查与治疗的冠心病患者234例,根据患者在术中使用对比剂剂量的不同将患者分为低剂量组(剂量200ml,n=127)和高剂量组(剂量≥200ml,n=107),比较两组患者术前、术后1d、术后7d肾功能相关指标血尿素氮(BUN)、血肌酐(sCr)、尿β2微球蛋白(尿β2MG)变化情况。结果低剂量组及高剂量组患者术后第1天,sCr、BUN、尿β2MG水平较术前显著上升,与治疗前相比,差异具有统计学意义(P0.05);术后第7天,sCr、BUN、尿β2MG水平较术后第1天有显著回落。术后第1天、第7天高剂量与低剂量组患者sCr、BUN、尿β2MG水平比较,差异具有统计学意义(P0.05)。结论冠脉造影可促进患者肾功能损害,随着剂量增加,其损害可能越重。     

阿托伐他汀改善对比剂对肾功能的短期影响

Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P ＜ 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P ＜ 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P ＞0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P ＞ 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P ＞0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P ＜ 0.01), but it had no significant change compared to day 2 after angiography (P ＞ 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P ＜ 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P ＜ 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P ＞ 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients.     

阿托伐他汀改善对比剂对肾功能的短期影响

Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P ＜ 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P ＜ 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P ＞0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P ＞ 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P ＞0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P ＜ 0.01), but it had no significant change compared to day 2 after angiography (P ＞ 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P ＜ 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P ＜ 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P ＞ 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients.     

阿托伐他汀改善对比剂对肾功能的短期影响

Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P ＜ 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P ＜ 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P ＞0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P ＞ 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P ＞0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P ＜ 0.01), but it had no significant change compared to day 2 after angiography (P ＞ 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P ＜ 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P ＜ 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P ＞ 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients.     

阿托伐他汀改善对比剂对肾功能的短期影响

Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P ＜ 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P ＜ 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P ＞0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P ＞ 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P ＞0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P ＜ 0.01), but it had no significant change compared to day 2 after angiography (P ＞ 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P ＜ 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P ＜ 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P ＞ 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients.     

阿托伐他汀改善对比剂对肾功能的短期影响

Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P ＜ 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P ＜ 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P ＞0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P ＞ 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P ＞0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P ＜ 0.01), but it had no significant change compared to day 2 after angiography (P ＞ 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P ＜ 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P ＜ 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P ＞ 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients.     

阿托伐他汀改善对比剂对肾功能的短期影响

Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P ＜ 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P ＜ 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P ＞0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P ＞ 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P ＞0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P ＜ 0.01), but it had no significant change compared to day 2 after angiography (P ＞ 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P ＜ 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P ＜ 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P ＞ 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients.     

阿托伐他汀改善对比剂对肾功能的短期影响

Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P ＜ 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P ＜ 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P ＞0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P ＞ 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P ＞0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P ＜ 0.01), but it had no significant change compared to day 2 after angiography (P ＞ 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P ＜ 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P ＜ 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P ＞ 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients.     

阿托伐他汀改善对比剂对肾功能的短期影响

Objective To study the effects of atorvastatin on contrast induced renal function change and plasma hsCRP in patients undergoing coronary angiography. Methods 120 patients who underwent coronary angiography were randomized to receive atorvastatin (20 mg/qn, n = 60) or no atorvastatin (n =60) treatment 2 to 3 days before coronary angiography. Urinary α1-MG, TRF and mALB were checked for evidence of tubular or glomendar damage at start, 1 day and 2 days after the administration of a radiocontrast agent. Serum creatinine, BUN, cystatin C and hsCRP levels were also assessed at the same time. Ccr and GFR were calculated according to Cockcroft-Ganh and GFR(ml/min) = 74. 835/Cys C1.333formulas basing on serum creatinine or cystatin C concentration. Results (1) In control group, comparison with the value before coronary angiography,urinary α1-MG, TRF and mALB or serum cystatin C and hsCRP significantly increased at day 1 after angiography (P ＜ 0.01). In comparison to the levels at day 1 after angiography, urinary α1-MG, TRF, mALB, serum cystatin C significantly decreased at day 2 after angiography(P ＜ 0.01), but α1-MG, cystatin C still exceeded the values before coronary angiography, TRF and mALB levels at day 2 after angiography had no significant change compared to baseline(P ＞0.05), hsCRP LeveL at day 2 after angiography had no significant change compared to that at day 1 after angiography (P ＞ 0.05) too. (2) In comparison with the value before coronary angiography in atorvastatin-treated group, the levels of urinary α1-MG, TRF and mALB or serum cystatin C at day 1 and day 2 after angiography had no significant change compared to baseline(P ＞0.05). Serum hsCRP significantly increased at day 1 after angiography compared to baseline(P ＜ 0.01), but it had no significant change compared to day 2 after angiography (P ＞ 0.05). (3)To compare to the atorvastatin-treated group, the values of urinary α1-MG, TRF and mALB or Cys C and hsCRP significantly increased at day 1 after angiography in control group (P ＜ 0.01), the values of urinary α1 -MG, cystatin C and hsCRP still significantly increased at day 2 (P ＜ 0.01) too, but those of TRF and mALB had no significantly change at day 1 or day 2 after angiography between the two groups (P ＞ 0.05). There was no significant change in BUN, Cr, Ccr levels before and after angiography between the two groups. Conclusions Low dose contrast induces light renal function damage. Pretreatment with atorvastatin 20 mg/qn for 2 to 3 days could significantly reduce procedural inflammatory reaction, attenuate urinary protein and the effect of degrading GFR in coronary angiography patients.